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Abstract
Background—The consequences of decentralizing prevention of mother-to-child HIV 
transmission and HIV-exposed infant services to antenatal care (ANC)/labor and delivery (L&D) 
sites from dedicated HIV care and treatment (C&T) centers remain unknown, particularly in low 
prevalence settings.
Methods—In a cohort of mother–infant pairs, we compared delivery of routine services at 
ANC/L&D and C&T facilities in Kinshasa, Democratic Republic of Congo from 2010–2013, 
using methods accounting for competing risks (eg, death). Women could opt to receive 
interventions at 90 decentralized ANC/L&D sites, or 2 affiliated C&T centers. Additionally, we 
assessed decentralization’s population-level impacts by comparing proportions of women and 
infants receiving interventions before (2009–2010) and after (2011–2013) decentralization.
Results—Among newly HIV-diagnosed women (N = 1482), the 14-week cumulative incidence 
of receiving the package of CD4 testing and zidovudine or antiretroviral therapy was less at 
ANC/L&D [66%; 95% confidence interval (CI): 63% to 69%] than at C&T (88%; 95% CI: 83% to 
92%) sites (subdistribution hazard ratio, 0.62; 95% CI: 0.55 to 0.69). Delivery of cotrimoxazole 
and DNA polymerase chain reaction testing to HIV-exposed infants (N = 1182) was inferior at 
ANC/L&D sites (subdistribution hazard ratio, 0.84; 95% CI: 0.76 to 0.92); the 10-month 
cumulative incidence of the package at ANC/L&D sites was 89% (95% CI: 82% to 93%) versus 
97% (95% CI: 93% to 99%) at C&T centers. Receipt of the pregnancy (20% of 1518, to 64% of 
1405) and infant (16%–31%) packages improved post decentralization.
Correspondence to: Andrew Edmonds, MSPH, PhD, 137 E. Franklin Street, CVS Plaza Building Suite 306, CB #8050, Chapel Hill, 
NC 27599-8050 (aedmonds@email.unc.edu). 
Presented in part at the 19th International AIDS Conference, July 22–27, 2012, Washington, DC (abstract THAE0103).
The authors have no conflicts of interest to disclose, but it was declared that money was paid to their institution, in grants, for the HIV 
program that provided the data for this study (grants were not for this data analysis; rather, they were for the overall program).
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML 
and PDF versions of this article on the journal’s Web site (www.jaids.com).
HHS Public Access
Author manuscript
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 May 04.
Published in final edited form as:
J Acquir Immune Defic Syndr. 2015 December 1; 70(4): e130–e139. doi:10.1097/QAI.
0000000000000781.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Conclusions—Services were delivered less efficiently at ANC/L&D sites than C&T centers. 
Although access improved with decentralization, its potential cannot be realized without sufficient 
and sustained support.
Keywords
prevention of mother to child transmission; vertical transmission; Democratic Republic of Congo; 
health services accessibility; delivery of health care; prenatal care/utilization; postnatal care/
utilization
INTRODUCTION
Access to prevention of mother-to-child HIV transmission (PMTCT) services has improved 
over time–the proportion of HIV-positive pregnant women who received antiretroviral 
(ARV) prophylaxis in the 21 African priority countries of the UNAIDS Global Plan1 
increased from 33% in 2009 to 68% in 2013.2 Despite this progress, this goal to reduce new 
pediatric HIV infections by 90% and halve AIDS-related maternal deaths by 2015 will not 
be achieved without improving the quality of service delivery and mitigating loss points 
throughout the PMTCT care continuum.3
After the identification of HIV infection during pregnancy, multiple steps are essential to 
minimize vertical transmission and assure long-term maternal and infant health.4,5 In 
resource-limited settings, barriers to effective HIV prevention and care often arise from 
deficiencies in the facilities where antenatal care (ANC), labor and delivery (L&D), and 
postpartum services are provided. For example, these sites regularly lack the CD4 
assessment capacity6–8 needed to appropriately prescribe antiretroviral therapy (ART).9 As 
PMTCT programs are pregnancy-focused10 and frequently in distinct physical locations 
lacking linkages to HIV care and treatment (C&T),11–13 there are also postnatal barriers 
including low uptake of ARV prophylaxis by infants14,15 and unavailability of diagnostic 
DNA polymerase chain reaction (PCR) testing.16
One strategy to increase coverage levels of maternal and infant interventions is 
decentralization, a shifting of services to primary care centers.17 Decentralization to ANC 
sites has yielded promising results — in South Africa18 and Rwanda19, for example, ART 
initiation by pregnant women was equivalent at decentralized and centralized sites. 
Decentralization of services in the Democratic Republic of Congo (DRC) has been 
extremely limited, paralleling the scale-up of other HIV services that has lagged behind in 
most other countries7 in the wake of civil wars and decades of political, social, and 
economic difficulties that impeded the development of vital health care infrastructures.20,21 
Few primary care clinics offer CD4 testing or efficacious ARV regimens for PMTCT22 
recommended by the World Health Organization (WHO). This is reflected in the 35% of 
Congolese HIV-infected pregnant women who received appropriate ARVs in 201323 and the 
2% who received a complete package of PMTCT services in 2012.22
The DRC, classified by UNAIDS as a focus country for pediatric HIV elimination,1 
accounted for 3% of new HIV infections in children in 2013 despite low prevalence among 
young women (0.5%).2 This burden is largely unmet, as evidenced by our network of 
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ANC/L&D sites in Kinshasa (the largest in this city of 10 million) identifying fewer than 
15% of pregnancies among HIV-infected women in 2008.24 Decentralizing PMTCT and 
HIV-exposed infant services in the DRC thus has significant potential to alleviate both 
regional and global burdens of maternal and pediatric HIV, although it is incompletely 
explored if the delivery of interventions at decentralized sites not historically accustomed to 
such provision, is on par with that at experienced, specialized sites. Furthermore, the 
population-level impacts of decentralization in low HIV prevalence areas remain unknown.
To increase program scope and coverage, we decentralized an expanded package of PMTCT 
and HIV-exposed infant services to 90 high-volume ANC/L&D sites in the resource-
deprived, low prevalence setting of Kinshasa. With the goal of informing program scale-up 
in similar implementation contexts, after rollout of new individual-level registers linking 
mother–infant pairs, this study had 2 aims. First, we assessed if intervention packages of 
CD4 testing and zidovudine (AZT) or ART for mothers, and DNA PCR testing and 
cotrimoxazole prophylaxis for infants were delivered as efficiently at decentralized 
ANC/L&D sites as at dedicated C&T centers. Secondly, we aimed to quantify the 
population-level impacts of decentralization by comparing the numbers and proportions of 
mothers and infants receiving the above intervention packages before and after their 
availability at ANC/L&D sites.
METHODS
Study Setting, Interventions, and Data Sources
In 2003, the University of North Carolina at Chapel Hill (UNC) initiated its HIV prevention, 
care, and treatment programs in the DRC (UNC-DRC) by strengthening Kinshasa 
ANC/L&D sites through the introduction of a minimum package of maternal and infant 
services, including HIV counseling and testing and PMTCT prophylaxis.25 This package, 
instituted in June 2010 in 37 of the city’s highest volume facilities, has been described 
previously.24–26
In April 2010, we began rolling out an expanded package to these sites, and 53 others (for a 
total of 90) were added by September 2012 to cover 32/35 provincial health zones. The prior 
standard of care was bolstered by training personnel on the 2010 WHO PMTCT 
guidelines27 that includes Option A, empathetic counseling skills, co-located delivery care, 
and the importance of patient retention, paying delivery fees to encourage safe birth, and 
providing (1) CD4 testing, cotrimoxazole, and AZT for mothers, and (2) cotrimoxazole, 
extended nevirapine, and DNA PCR testing for infants. Transportation costs to the first visit 
at either of 2 affiliated (but separately located) HIV C&T centers were provided to promote 
long-term care uptake; however, once the new interventions were available at ANC/L&D 
sites, women could opt to remain there for PMTCT and HIV-exposed infant services. At 45 
sites, volunteer HIV-infected “mother-mentors” worked as clinic assistants, helping women 
to navigate care while encouraging C&T uptake. Generally, women with CD4 counts ≤350 
could access ART at C&T centers only. Details on the ANC/L&D sites are outlined in Table 
S1 (see Supplemental Digital Content, http://links.lww.com/QAI/A726).
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An essential expanded package component was a new paper register that allowed for 
mothers and their infants to be linked and longitudinally tracked. Service delivery and 
patient dispositions were recorded in the registers by the ANC/L&D site providers and 
UNC-DRC personnel, who made supportive supervisory monitoring visits monthly as part 
of the expanded package. Data were recorded between a woman’s presentation for ANC or 
L&D, until her infant was confirmed as HIV-infected or ruled out as HIV-uninfected. Details 
on the populations of mothers and infants tracked in the registers are presented in Table S2 
(see Supplemental Digital Content, http://links.lww.com/QAI/A726).
The study sites included the 90 ANC/L&D sites and 2 UNC-DRC C&T centers, Kalembe 
Lembe Pediatric Hospital and Bomoi Healthcare Center.28,29 The data sources were the 
registers at the ANC/L&D sites, which were entered into an Epi Info database, the real-time 
Epi Info database at the C&T centers,30 and an aggregate service delivery database from the 
ANC/L&D sites used to provide program context and quantify decentralization’s 
population-level impacts. The Epi Info databases contained unique patient identifiers to link 
mother–infant pairs and were linked to each other, as the ANC/L&D database included C&T 
codes and the C&T database included ANC/L&D codes. This facilitated tracking of 
individuals between facility types. All database records as of July 2013, when data 
collection ended, were included in analyses.
Measures and Analyses
In the service delivery aim, we calculated the cumulative incidence of 2 outcomes between 
2010 and 2013: (1) receipt of CD4 testing, and AZT or ART (pregnancy package), by 
women newly diagnosed with HIV before L&D, and (2) receipt of DNA PCR testing and 
cotrimoxazole (infant package) by HIV-exposed infants, at 2 facility types: (1) ANC/L&D 
site, providing decentralized services, and (2) C&T center, specialized to deliver these 
services. In the analysis of women, follow-up began at C&T enrollment if the pregnancy was 
registered at a site before it began offering CD4 testing and AZT; otherwise, follow-up 
began at ANC presentation. Follow-up ended at the earliest of (1) the outcome, (2) censoring 
(loss to follow-up, transfer, move, voluntary withdrawal, or end of study), or (3) a competing 
risk (delivery, miscarriage, or death). In the infant analysis, follow-up began on the date of 
first visit at ≥1 month of age (when cotrimoxazole is indicated31) at a facility offering DNA 
PCR testing and cotrimoxazole. Additionally, reaching 18 months of age (the end of the 
early infant diagnosis period, when HIV can be serologically confirmed) was an additional 
censoring event, and competing risks were limited to death and confirmation of HIV-
negative status.
As individuals could opt to receive services at a C&T center, exposure could switch from 
“decentralized” to “specialized” (but not vice-versa) if this transfer occurred before either 
component of the intervention package was received; if 1 of the outcome services was 
received, followup was censored on the transfer date (date of C&T enrollment). To allow for 
this late entry, we used the counting process configuration as applied by Geskus.32 
Individuals who received the intervention package on their enrollment date and those lost 
after a single visit33 were assigned a follow-up time of 1 day. For others censored, if deemed 
lost to follow-up after a missed visit, follow-up ended on the last visit date. Only newly HIV-
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diagnosed women were eligible because the outcome included ARV receipt, and many 
previously diagnosed women were already on ART; additionally, time in care was likely a 
confounder and modifier of the associations of interest. Infants were eligible for the infant 
analysis even if their mothers were not in the analysis of women. DNA PCR testing was 
defined as specimen collected, not also receipt of result.
Competing risks are events such as death that preclude occurrence of the outcome and can 
create bias.34 To account for competing risks in our data, the SAS macro %PSHREG was 
used to obtain competing risk cumulative incidence functions stratified by facility type 
(decentralized versus specialized) and to quantify the effects of facility type on delivery of 
the intervention packages.35 Crude and adjusted hazard ratios (HRs) and 95% confidence 
intervals (CIs) were generated using the Fine and Gray subdistribution hazards model,36 
which produces an effect measure due to both the association of the exposure on the event of 
interest and the possibly differential impact of competing events on exposed and unexposed 
individuals.37 We also employed the cause-specific Cox proportional hazards model, which 
treats competing events as censored, and results in biased effect estimates if its inherent 
assumption of independence between the outcome and competing events is incorrect.37
Causal diagrams were used to identify confounders for adjusted models.38 In the analysis of 
women, covariates were age and gestational age at registration along with CD4 count during 
pregnancy; infant analysis covariates were age at first visit and 3 maternal factors: 
gestational age, HIV status (undiagnosed or previously diagnosed) at registration, and CD4 
count during pregnancy. We employed multiple imputation with fully conditional 
specification methods39 to account for missing covariate data; 5 imputed datasets were 
generated. To relax the linearity assumption in modeling continuous variables, we used 
Stone and Koo’s additive splines constrained to be linear in the tails, with knots at the fifth, 
35th, 65th, and 95th percentiles. χ2 or Cochran-Armitage trend tests were used to compare 
proportions, with medians compared by the Mann–Whitney test.40
In the aim to quantify decentralization’s population-level impacts, we calculated the 
proportions of HIV-infected women who received the pregnancy package pre-
decentralization (at affiliated C&T centers only) versus post-decentralization (at either the 
C&T centers or ANC/L&D sites). Similarly, proportions of their HIV-exposed infants who 
received the infant package, pre- and post-decentralization, were calculated. All analyses 
were completed in SAS 9.3 (SAS Institute Inc., Cary, NC).
Ethical Approval
The study was approved by the Kinshasa School of Public Health Ethics Committee and the 
UNC Institutional Review Board. Consent was obtained at C&T enrollment; activities at the 
ANC/L&D sites met criteria for waiver of consent.
RESULTS
Aim 1: Service Delivery
Between 2010 and 2013, in our cohort of linked mother–infant pairs, we identified 1482 
newly HIV-diagnosed women eligible for the analysis of CD4 testing and ARV regimen 
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delivery during pregnancy, as well as 1142 HIV-exposed infants eligible for the analysis of 
DNA PCR testing and cotrimoxazole delivery. Their characteristics and outcomes are 
described in Table 1. Women at a C&T center did not differ from those at only a ANC/L&D 
site in terms of age (P = 0.88) or gestational age (P = 0.05) at registration. The cumulative 
incidence of receiving the pregnancy package at 14 weeks was less at the ANC/L&D sites 
(66%; 95% CI: 63% to 69%) than that at the C&T centers (88%; 95% CI: 83% to 92%) (Fig. 
1), and both the unadjusted (0.59; 95% CI: 0.51 to 0.69) and adjusted (0.62; 95% CI: 0.55 to 
0.69) subdistribution HRs indicate inferior delivery of the package at the ANC/L&D sites 
compared with the C&T centers (Table 2). No marked changes in delivery of the package 
over time at either facility type were noted.
Compared with infants at a C&T center, those only at an ANC/L&D site were older at first 
visit (P < 0.01) and more likely had mothers who were previously HIV undiagnosed (P = 
0.01), of greater gestational age (P < 0.01) at registration, healthier as reflected by pregnancy 
CD4 count (P < 0.01), and did not receive AZT or ART (P < 0.01). The cumulative 
incidences of receiving the infant package at 10 months (Fig. 1) at the ANC/L&D sites 
(89%; 95% CI: 82% to 93%) and the C&T centers (97%; 95% CI: 93% to 99%), as well as 
the unadjusted (0.85; 95% CI: 0.75 to 0.97) and adjusted (0.84; 95% CI: 0.76 to 0.92) 
subdistribution HRs (Table 2), suggest that delivery of the package at the ANC/L&D sites 
was poorer than that at the C&T centers. No marked changes in delivery of the package over 
time at either facility type were noted. Using age rather than months in care as the timescale, 
the median age at package receipt at the ANC/L&D sites was 7.3 weeks (interquartile range, 
6.6–11.7), similar to that at the C&T sites (7.0 weeks; interquartile range, 6.4–8.9).
Only 14.2% of newly diagnosed cases remaining at the ANC/L&D sites received all 4 
components of the pregnancy and infant packages, markedly lower than the 53.5% observed 
among cases at the C&T centers (Fig. 2). Altogether, just 21.1% of total newly diagnosed 
cases received all 4 components of the packages, which emphasizes that overall impact was 
driven more by the ANC/L&D sites where most individuals remained for care.
Aim 2: Population-Level Impacts of Decentralization
During the pre-decentralization period of 2009–2010, considering all HIV-infected pregnant 
women identified at ANC/L&D sites including those not presenting to C&T (N = 1518), 
package uptake at affiliated C&T centers was approximately 20% (pregnancy) and 16% 
(infant). In 2011–2013 when services were decentralized (N = 1405), uptake across facilities 
increased to about 64% (pregnancy) and 31% (infant). These increases are depicted in Fig. 3. 
During the period of decentralization, 1260 women and 634 infants received at least 1 
intervention at an ANC/L&D site; no temporal changes in pregnancy and infant package 
uptake were noted. Greater proportions of women (P < 0.01) and infants (P < 0.01) remained 
at ANC/L&D sites in later years (Table 1), reflecting the increased dissemination of 
decentralized services over time.
DISCUSSION
This study, by using a novel system to link and track mother–infant pairs in Kinshasa, DRC, 
revealed that decentralized primary care facilities focused on ANC/L&D delivered PMTCT 
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and HIV-exposed infant services less efficiently than specialized HIV C&T centers. The 
finding held true for the pregnancy package of CD4 testing and AZT or ART (HR, 0.62; 
95% CI: 0.55 to 0.69) as well as the infant package of DNA PCR testing and cotrimoxazole 
(HR, 0.84; 95% CI: 0.76 to 0.92), and provides unique evidence on integration called 
“urgently needed” in a recent systematic review.41 As PMTCT and HIV-exposed infant 
services are increasingly incorporated into primary care in conjunction with the accelerating 
global scale-up of WHO Options B/B+,42 our work provides a caution to program 
implementers that even with sustained commitment to training, capacity, and monitoring and 
evaluation (M&E), optimal service delivery may be harder to attain at decentralized sites.
Despite the noted discrepancies between facility types, performance at the ANC/L&D sites 
was encouraging. At these sites, the cumulative incidences of the pregnancy and infant 
packages were 66% and 89%, respectively, and substantial proportions of the populations 
received the interventions on their first day in care. Uptake of interventions by both mothers 
and infants increased dramatically post-decentralization, resulting in greater absolute 
numbers of individuals reached, as observed in Nigeria.43 There were specific areas where 
the C&T centers appeared to outperform, including CD4 testing (98% of women versus 
67%), as observed in Rwanda,19 and provision of services at visits during later follow-up, 
consistent with personnel at dedicated sites having a deeper understanding of the need for 
HIV-related care. These differences inform the selection of strategies to improve service 
delivery in other contexts, for example point-of-care assays44,45 (which were unavailable at 
the ANC/L&D sites) and integrating HIV interventions into routine clinical encounters such 
as infant immunization visits.46
The new register and data systems were instrumental in providing a detailed, individual-level 
picture of our populations for the first time. Notably, these low-tech tools were successfully 
implemented in a resource-constrained environment, responding to calls for strengthening of 
PMTCT systems to improve health,47–49 targeting areas for improvement, and 
demonstrating the feasibility of such innovations in similar settings. Despite rigorous M&E 
and retention efforts, there was frequent loss to follow-up of mothers and infants, 
particularly at ANC/L&D sites (Table 1; Fig. 2), and between delivery and first infant visit 
(Fig. 2; see Table S1, Supplemental Digital Content, http://links.lww.com/QAI/A726). 
Programs decentralizing services must actively combat this phenomenon, which negatively 
impacts outcomes and their assessment. Accordingly, an inadequate percentage of women 
ultimately had their infants DNA PCR tested–Fig. 2 shows high attrition, as commonly 
noted,50 regardless of facility type. Programs experiencing attrition should employ a 
multifocal approach with tactics such as peer support,51 cash transfers,52 and maternal ART 
provision,53 to mitigate loss across the cascade.
Study strengths include examining relevant outcomes (eg, CD4 testing; maternal 
immunological assessment will occur in an Option B context upon completion of 
breastfeeding, and in an Option B+ context during ART follow-up), high generalizability 
because evaluated ANC/L&D sites were locally administered and were not research 
facilities, and intensive M&E and training that likely resulted in superior data quality and 
improved service delivery. We believe that stronger magnitudes of effect favoring the C&T 
centers would have been noted without our strong caliber of technical support to the 
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ANC/L&D sites, and that decentralized sites lacking such support would underperform 
relative to the ANC/L&D sites in this study. As the study was in a low HIV prevalence 
context, it provides valuable information for programs in declining prevalence settings while 
demonstrating that low prevalence does not imply low unmet need. An additional strength is 
the competing risks methodology, although in this application, Fine and Gray models 
yielded effect measures not appreciably different than those from traditional Cox 
Proportional Hazards models, due to the timing and low frequency of competing events. The 
presence of competing risks in implementation settings and aim to affect policy37 informed 
the chosen methodological approach, which precluded questions of possible bias had 
competing risks not been taken into account.
Study limitations include (1) inconsistent recording of extended nevirapine initiation, which 
prevented its inclusion in the infant package, (2) rarely assessing WHO HIV clinical stage, 
precluding its use as a covariate, and (3) not collecting the data necessary to see if there were 
sociodemographic differences between women at ANC/L&D and C&T sites. We were not 
able to evaluate if effects were heterogeneous across ANC/L&D sites due to limited sample 
size, and we also lacked data on receipt of DNA PCR test result, an important PMTCT 
indicator. Although it is possible that women who presented at a C&T center or were in 
contact with a “mother-mentor” were more motivated to follow through with care for 
themselves and their infants, thus potentially impacting results, we believe that service 
delivery was primarily provider-driven. Relatedly, we speculated that a woman’s health 
status (as reflected by her CD4 count) might influence a provider’s likelihood of delivering 
services, and hence this factor was included in adjusted analyses.
In conclusion, decentralization of PMTCT and HIV-exposed infant services is a structural 
intervention with great promise to help meet global benchmarks to reduce pediatric HIV, as 
evidenced by the observed increase in package uptake post-decentralization and the 
encouraging performance by ANC/L&D sites in delivering key interventions. However, our 
results also suggest that if the approach is to be maximally effective, efforts to integrate such 
services into primary care must be accompanied by training and support that are sufficient 
and sustained, as well as requisite systems for the M&E of impact. This message should be 
considered in decision-making on resource allocation and program implementation.
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FIGURE 1. 
Cumulative incidence of delivery of CD4 testing, and AZT or ART, to women newly 
diagnosed with HIV during pregnancy (A) and cotrimoxazole and DNA PCR testing to HIV-
exposed infants (B), by facility type, Kinshasa, Democratic Republic of Congo, 2010–2013. 
Bands represent 95% CIs. A, The cumulative incidence function is estimated at the mean 
values of (1) age at registration, (2) gestational age at registration, and (3) CD4 count during 
pregnancy. B, The cumulative incidence function is estimated at the mean values of (1) age 
at first visit at ≥1 month of age, (2) maternal gestational age at registration, and (3) maternal 
CD4 count during pregnancy (a proxy for HIV disease progression), as well as the reference 
level for maternal HIV status (undiagnosed, rather than previously diagnosed). If gestational 
age at registration was not recorded, it was estimated using projected date of delivery and 
otherwise date of delivery (if available).
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FIGURE 2. 
Cascade of PMTCT and HIV-exposed infant services by facility type, Kinshasa, Democratic 
Republic of Congo, 2010–2013. The percentages represent the counts of infants who have 
received a DNA PCR test divided by the total number of newly diagnosed women (eg, 
173/1222 = 14.2%), not cumulative incidences.
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FIGURE 3. 
Population-level impacts of decentralization on uptake of pregnancy and infant packages, 
Kinshasa, Democratic Republic of Congo, 2009–2013. The pregnancy package is CD4 
testing and AZT or ART; the infant package is cotrimoxazole and DNA PCR testing.
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TABLE 1
Characteristics and Outcomes of HIV-Infected Women and Their HIV-Exposed Infants Included in Cumulative 
Incidence Analyses, Kinshasa, Democratic Republic of Congo, 2010–2013*
Women Newly Diagnosed With HIV During Pregnancy
(If ANC/L&D Site Person-Time, Pregnancy Registered 
While Decentralized CD4 Testing and AZT Available)
At ANC/L&D Site Only 
(N = 1222)
At Affiliated HIV C&T 
Center for All or Part of 
Follow-up† N = 260) Total (N = 1482)
Year of registration, n (%)
 2010   0 (0.0)   77 (29.6) 77 (5.2)
 2011 151 (12.4) 176 (67.7) 327 (22.1)
 2012 677 (55.4)   6 (2.3) 683 (46.1)
 2013 394 (32.2)   1 (0.4) 395 (26.7)
Age at registration, median (IQR),‡ yrs     29 (25–34)     30 (25–34)    29 (25–34)
Gestational age at registration, median (IQR),§ wks     22 (18–28)     22 (17–26)    22 (18–28)
WHO HIV clinical stage at registration, n (%)
 1 403 (33.0) 16 (6.2) 419 (28.3)
 2 63 (5.2)   0 (0.0) 63 (4.3)
 3 13 (1.1)   0 (0.0) 13 (0.9)
 4   3 (0.2)   0 (0.0)   3 (0.2)
 Not assessed   740 (60.6) 244 (93.8) 984 (66.4)
Referred to affiliated HIV C&T center, n (%)
 No 988 (80.9) 0 (0.0) 988 (66.7)
 Yes 234 (19.1) 260 (100.0) 494 (33.3)
CD4 test during pregnancy, n (%)
 No 407 (33.3)   6 (2.3)   413 (27.9)
 Yes 815 (66.7) 254 (97.7) 1069 (72.1)
  ≤350∥       397 (50.7)       108 (45.6)      505 (49.5)
  >350       386 (49.3)       129 (54.4)      515 (50.5)
CD4 count during pregnancy, median (IQR)¶   347 (223–506)   379 (235–577)   353 (227–519)
Antiretroviral regimen during pregnancy, n (%)
 None 188 (15.4) 21 (8.1)   209 (14.1)
 AZT 927 (75.9) 142 (54.6) 1069 (72.1)
 Triple-drug ART 107 (8.8)   97 (37.3)   204 (13.8)
Outcome,# n (%)
 CD4 testing, and AZT or ART 730 (59.7) 234 (90.0) 964 (65.0)
 Delivered** 197 (16.1) 23 (8.8) 220 (14.8)
 Lost to follow-up 231 (18.9)   1 (0.4) 232 (15.7)
 Miscarriage or died   6 (0.5)   2 (0.8)   8 (0.5)
 Transferred, moved, or voluntarily withdrew 43 (3.5)   0 (0.0) 43 (2.9)
 Pregnant at study end 15 (1.2)   0 (0.0) 15 (1.0)
HIV-Exposed Infants At ANC/L&D Site Only 
(N = 718)
At Affiliated HIV C&T 
Center for All or Part of 
Follow-up†† (N = 424)
Total (N = 1142)
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Women Newly Diagnosed With HIV During Pregnancy
(If ANC/L&D Site Person-Time, Pregnancy Registered 
While Decentralized CD4 Testing and AZT Available)
At ANC/L&D Site Only 
(N = 1222)
At Affiliated HIV C&T 
Center for All or Part of 
Follow-up† N = 260) Total (N = 1482)
(If ANC/L&D Site Person-Time, First Visit at ≥ 1 mo of 
Age While Decentralized Cotrimoxazole and DNA PCR 
Testing Available)
Year of first visit at ≥1 mo of age, n (%)
 2010   0 (0.0) 17 (4.0) 17 (1.5)
 2011 234 (32.6) 223 (52.6) 457 (40.0)
 2012 320 (44.6) 134 (31.6) 454 (39.8)
 2013 164 (22.8)   50 (11.8) 214 (18.7)
Age at first visit at ≥1 mo of age, median (IQR), wks       6.7 (6.4–7.4)    6.6 (6.0–7.3)   6.7 (6.3–7.3)
Maternal HIV status at registration, n (%)
 Previously diagnosed 208 (29.0) 156 (36.8) 364 (31.9)
 Undiagnosed 510 (71.0) 268 (63.2) 778 (68.1)
Maternal pregnancy stage at registration,§ n (%)
 ≤28 wks 430 (59.9) 330 (77.8) 760 (66.5)
 >28 wks, before labor and delivery 143 (19.9) 54 (12.7) 197 (17.3)
 Unknown, before labor and delivery   0 (0.0)   1 (0.2)   1 (0.1)
 Labor and delivery 145 (20.2) 39 (9.2) 184 (16.1)
Maternal gestational age at registration, median (IQR),§ wks   26 (20–36)   24 (18–28)   24 (20–32)
Maternal WHO HIV clinical stage at registration, n (%)
 1 133 (18.5) 79 (18.6) 212 (18.6)
 2 29 (4.0) 26 (6.1) 55 (4.8)
 3   5 (0.7) 16 (3.8) 21 (1.8)
 4   1 (0.1)   2 (0.5)   3 (0.3)
 Not assessed 550 (76.6) 301 (71.0) 851 (74.5)
Maternal CD4 test during pregnancy, n (%)
 No 421 (58.6) 115 (27.1) 536 (46.9)
 Yes 297 (41.4) 309 (72.9) 606 (53.1)
  ≤350∥    102 (35.5)    157 (53.2)   259 (44.5)
  >350    185 (64.5)    138 (46.8)   323 (55.5)
Maternal CD4 count during pregnancy, median (IQR)¶   421 (284–559)   336 (218–504)   378 (248–545)
Maternal antiretroviral regimen during pregnancy, n (%)
 None 254 (33.4)   49 (11.6) 303 (26.5)
 AZT 318 (44.3) 143 (33.7) 461 (40.4)
 Triple-drug ART 146 (20.3) 232 (54.7) 378 (33.1)
Extended nevirapine, n (%)
 No 39 (5.4) 26 (6.1)   65 (5.7)
 Yes 679 (94.6) 398 (93.9) 1077 (94.3)
Cotrimoxazole, n (%)
 No 109 (15.2) 22 (5.1)   131 (11.4)
 Yes 609 (84.8) 409 (94.9) 1018 (88.6)
DNA PCR test, n (%)
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Women Newly Diagnosed With HIV During Pregnancy
(If ANC/L&D Site Person-Time, Pregnancy Registered 
While Decentralized CD4 Testing and AZT Available)
At ANC/L&D Site Only 
(N = 1222)
At Affiliated HIV C&T 
Center for All or Part of 
Follow-up† N = 260) Total (N = 1482)
 No 131 (18.2) 22 (5.6) 153 (13.3)
 Yes 587 (81.8) 409 (94.4) 996 (86.7)
   Positive‡‡    20 (3.8)   23 (5.7)   43 (4.6)
   Negative    503 (96.2)    379 (94.3)   882 (95.4)
Outcome,# n (%)
 Cotrimoxazole and DNA PCR test 562 (78.3) 398 (93.9) 960 (84.1)
 Reached 18 mo of age   0 (0.0)   1 (0.2)   1 (0.1)
 Lost to follow-up 144 (20.1)   3 (0.7) 147 (12.9)
 Died   0 (0.0)   3 (0.7)   3 (0.3)
 Transferred, moved, or voluntarily withdrew   9 (1.3)   2 (0.5) 11 (1.0)
 Under follow-up at study end   3 (0.4) 17 (4.0) 20 (1.8)
*
Data from ANC/L&D sites (2 of 90 had zero registered pregnancies) and 2 affiliated HIV C&T centers.
†
Twelve women contributed person-time at both an ANC/L&D site and an HIV C&T center.
‡Among 1336 pregnancies where the woman’s date of birth was recorded.
§Among pregnancies with actual or projected gestational age. If gestational age at registration was not recorded, it was estimated using projected 
date of delivery and otherwise date of delivery (if available).
∥
Denominator: Non-missing CD4 results.
¶Among non-missing CD4 results.
#
Proportions, not cumulative incidences.
**
Includes 16 women without a recorded delivery date who were projected, at study end, to have delivered.
††
Eleven infants contributed person-time at both an ANC/L&D site and an HIV C&T center.
‡‡
Denominator: Non-missing DNA PCR results.
IQR, interquartile range.
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